Impact of non-alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi-cohort longitudinal study

被引:1
|
作者
Zhao, Lijun [1 ,2 ,3 ]
Zeng, Qingyue [1 ]
Zhou, Xiaoqin [4 ,5 ]
Tang, Linqiao [6 ]
Wang, Yujia [7 ]
Han, Qianqian [8 ]
Zou, Yutong [2 ,3 ]
Xiao, Xiang [2 ,3 ]
Liu, Ke [2 ,3 ]
Ju, Xuegui [2 ,3 ]
Wu, Yucheng [2 ,3 ]
Li, Xingyuan [2 ,3 ]
Zhao, Chuanyi [2 ,3 ]
Liu, Fang [2 ,3 ]
机构
[1] Sichuan Univ, West China Hosp, Dept Gen Practice Ward, Int Med Ctr Ward,Gen Practice Med Ctr, Chengdu, Peoples R China
[2] Sichuan Univ, Dept Nephrol, West China Hosp, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
[3] Sichuan Univ, Kidney Res Inst, Lab Diabet Kidney Dis, West China Hosp, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China
[4] Sichuan Univ, West China Hosp, Res Ctr Clin Epidemiol & Evidence Based Med, Chengdu, Peoples R China
[5] Sichuan Univ, West China Hosp, Ctr Biostat Design Measurement & Evaluat CBDME, Dept Clin Res Management, Chengdu, Peoples R China
[6] Sichuan Univ, Res Core Facil, West China Hosp, Chengdu, Peoples R China
[7] Sichuan Univ, West China Sch Med, Dept Undergrad Students, Chengdu, Peoples R China
[8] Sichuan Univ, West China Hosp, Dept Pathol, Chengdu, Peoples R China
来源
DIABETES OBESITY & METABOLISM | 2024年 / 26卷 / 10期
基金
中国国家自然科学基金;
关键词
cardio-cerebrovascular diseases; chronic kidney disease; diabetes; end-stage kidney disease; mortality; non-alcoholic fatty liver disease; ASSOCIATION; NEED;
D O I
10.1111/dom.15758
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To evaluate the impact of non-alcoholic fatty liver disease (NAFLD) presence and fibrosis risk on adverse outcomes in patients with type 2 diabetes and chronic kidney disease. Methods: Data were sourced from two longitudinal cohorts: 1172 patients from the National Health and Nutrition Examination Survey (NHANES) and 326 patients from the kidney biopsy cohort at the West China Hospital of Sichuan University. Cox regression estimated hazard ratios (HRs) for NAFLD and liver fibrosis concerning adverse clinical outcomes. Subsequently, a two-sample Mendelian randomization study using genome-wide association study statistics explored NAFLD's potential causal link to cardio-cerebrovascular events. Results: In the NHANES cohort, NAFLD stood as an independent risk factor for various outcomes: overall mortality [HR 1.53 (95% confidence interval, CI 1.21-1.95)], mortality because of cardio-cerebrovascular diseases [HR 1.63 (95% CI 1.12-2.37)], heart disease [HR 1.58 (95% CI 1.00-2.49)], and cerebrovascular disease [HR 3.95 (95% CI 1.48-10.55)]. Notably, advanced liver fibrosis, identified by a fibrosis-4 (FIB-4) score >2.67, exhibited associations with overall mortality, cardio-cerebrovascular disease mortality and heart disease mortality. Within the kidney biopsy cohort, NAFLD correlated with future end-stage kidney disease [ESKD; HR 2.17 (95% CI 1.41-3.34)], while elevated FIB-4 or NAFLD Fibrosis Scores predicted future ESKD, following full adjustment. Liver fibrosis was positively correlated with renal interstitial fibrosis and tubular atrophy in biopsies. Further Mendelian randomization analysis supported a causal relationship between NAFLD and cardio-cerebrovascular events. Conclusions: In patients with type 2 diabetes and chronic kidney disease, the NAFLD presence and elevated FIB-4 scores link to heightened mortality risk and ESKD susceptibility. Moreover, NAFLD shows a causal relationship with cardio-cerebrovascular events.
引用
收藏
页码:4241 / 4250
页数:10
相关论文
共 50 条
  • [31] Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-Dm2 study
    Jesus Martinez-Ortega, Antonio
    Pinar Gutierrez, Ana
    Lara-Romero, Carmen
    Remon Ruiz, Pablo Jesus
    Ampuero-Herrojo, Javier
    De Lara-Rodriguez, Irene
    Romero-Gomez, Manuel
    Luna, Pedro P. Garcia
    Soto-Moreno, Alfonso
    NUTRICION HOSPITALARIA, 2022, 39 (05) : 1012 - 1018
  • [32] Prevalence and Risk Factors of Hyperuricemia in Patients with Chronic Kidney Disease and Non-Alcoholic Fatty Liver
    Golmohammadi, Sima
    Tavasolil, Marjan
    Asadi, Nadia
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2020, 13 : 299 - 304
  • [33] Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease
    Kanbay, Mehmet
    Bulbul, Mustafa C.
    Copur, Sidar
    Afsar, Baris
    Sag, Alan A.
    Siriopol, Dimitrie
    Kuwabara, Masanari
    Badarau, Silvia
    Covic, Adrian
    Ortiz, Alberto
    JOURNAL OF NEPHROLOGY, 2021, 34 (03) : 649 - 659
  • [34] Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes
    Li, Mian
    Zhao, Zhiyun
    Qin, Guijun
    Chen, Li
    Lu, Jieli
    Huo, Yanan
    Chen, Lulu
    Zeng, Tianshu
    Xu, Min
    Chen, Yuhong
    Wang, Tiange
    Wang, Shuangyuan
    Xu, Yiping
    Shi, Lixin
    Tang, Xulei
    Su, Qing
    Yu, Xuefeng
    Yan, Li
    Wan, Qin
    Chen, Gang
    Gao, Zhengnan
    Wang, Guixia
    Shen, Feixia
    Luo, Zuojie
    Zhang, Yinfei
    Liu, Chao
    Wang, Youmin
    Hu, Ruying
    Ye, Zhen
    Wu, Shengli
    Deng, Huacong
    Yang, Tao
    Li, Qiang
    Qin, Yingfen
    Mu, Yiming
    Zhao, Jiajun
    Ning, Guang
    Bi, Yufang
    Xu, Yu
    Wang, Weiqing
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2021, 124
  • [35] Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study
    Akahane, Takemi
    Akahane, Manabu
    Namisaki, Tadashi
    Kaji, Kosuke
    Moriya, Kei
    Kawaratani, Hideto
    Takaya, Hiroaki
    Sawada, Yasuhiko
    Shimozato, Naotaka
    Fujinaga, Yukihisa
    Furukawa, Masanori
    Kitagawa, Koh
    Ozutsumi, Takahiro
    Tsuji, Yuki
    Kaya, Daisuke
    Mitoro, Akira
    Yoshiji, Hitoshi
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
  • [36] FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease
    Seko, Yuya
    Yano, Kohta
    Takahashi, Aya
    Okishio, Shinya
    Kataoka, Seita
    Okuda, Keiichiroh
    Mizuno, Naoki
    Takemura, Masashi
    Taketani, Hiroyoshi
    Umemura, Atsushi
    Nishikawa, Taichiro
    Yamaguchi, Kanji
    Moriguchi, Michihisa
    Okanoue, Takeshi
    Itoh, Yoshito
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [37] Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease
    Chan-Young Jung
    Geun Woo Ryu
    Hyung Woo Kim
    Sang Hoon Ahn
    Seung Up Kim
    Beom Seok Kim
    Diabetologia, 2022, 65 : 518 - 527
  • [38] Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease
    Kaps, Leonard
    Labenz, Christian
    Galle, Peter R.
    Weinmann-Menke, Julia
    Kostev, Karel
    Schattenberg, Joern M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (08) : 942 - 948
  • [39] Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
    Mantovani, Alessandro
    Dalbeni, Andrea
    Beatrice, Giorgia
    Cappelli, Davide
    Gomez-Peralta, Fernando
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [40] Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients
    G. Targher
    L. Bertolini
    M. Chonchol
    S. Rodella
    G. Zoppini
    G. Lippi
    L. Zenari
    E. Bonora
    Diabetologia, 2010, 53 : 1341 - 1348